TXG 10x Genomics Inc

Price (delayed)

$54.99

Market cap

$7.23B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.52

Enterprise value

$6.78B

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 36
Highlights
TXG's EPS is up by 17% year-on-year and by 12% since the previous quarter
10x Genomics's debt has decreased by 13% YoY and by 3.8% QoQ
The company's quick ratio rose by 15% YoY but it fell by 11% QoQ
10x Genomics's revenue has decreased by 3.6% YoY

Key stats

What are the main financial stats of TXG

TXG stock price

How has the 10x Genomics stock price performed over time
Intraday
-5.5%
1 week
-15.47%
1 month
-21.29%
1 year
246.07%
YTD
237.16%
QTD
-39.14%

Financial performance

How have 10x Genomics's revenue and profit performed over time
Revenue
$618.58M
Gross profit
$444.65M
Operating income
-$72.2M
Net income
-$67.08M
Gross margin
71.9%
Net margin
-10.8%
TXG's operating income is up by 21% year-on-year and by 18% since the previous quarter
10x Genomics's operating margin has increased by 18% QoQ and by 18% YoY
The company's net income rose by 12% YoY and by 11% QoQ
10x Genomics's net margin has increased by 11% QoQ and by 9% YoY

Price vs fundamentals

How does TXG's price correlate with its fundamentals

Growth

What is 10x Genomics's growth rate over time

Valuation

What is 10x Genomics stock price valuation
P/E
N/A
P/B
8.55
P/S
11.63
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.96
TXG's EPS is up by 17% year-on-year and by 12% since the previous quarter
The P/B is 36% above the 5-year quarterly average of 6.3 and 32% above the last 4 quarters average of 6.5
TXG's equity is up by 7% year-on-year
The stock's price to sales (P/S) is 34% more than its last 4 quarters average of 8.7 and 32% more than its 5-year quarterly average of 8.8
10x Genomics's revenue has decreased by 3.6% YoY

Efficiency

How efficient is 10x Genomics business performance
The ROE has grown by 20% YoY and by 12% from the previous quarter
TXG's ROA is up by 19% YoY and by 11% from the previous quarter
TXG's ROS is up by 13% since the previous quarter and by 8% year-on-year
The return on invested capital is up by 10% since the previous quarter but it has declined by 6% year-on-year

Dividends

What is TXG's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TXG.

Financial health

How did 10x Genomics financials performed over time
The company's quick ratio rose by 15% YoY but it fell by 11% QoQ
The current ratio has grown by 14% YoY but it has contracted by 10% from the previous quarter
10x Genomics's debt is 91% lower than its equity
10x Genomics's debt to equity has decreased by 18% YoY and by 10% QoQ
10x Genomics's debt has decreased by 13% YoY and by 3.8% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.